ADGI
Income statement / Annual
Last year (2024), Adagio Therapeutics, Inc.'s total revenue was $25.38 M,
and the percentage change from the previous year is not available.
In 2024, Adagio Therapeutics, Inc.'s net income was -$169.93 M.
See Adagio Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2021
|
| Period Ended |
12/31/2024 |
12/31/2021 |
| Operating Revenue |
$25.38 M |
$0.00 |
| Cost of Revenue |
$1.62 M
|
$0.00
|
| Gross Profit |
$23.77 M
|
$0.00
|
| Gross Profit Ratio |
0.94
|
0
|
| Research and Development Expenses |
$137.25 M
|
$182.89 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$63.39 M
|
$36.52 M
|
| Other Expenses |
$0.00
|
$7.50 M
|
| Operating Expenses |
$200.64 M
|
$226.91 M
|
| Cost And Expenses |
$202.26 M
|
$226.91 M
|
| Interest Income |
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$1.43 M
|
| EBITDA |
-$176.88 M |
-$225.36 M |
| EBITDA Ratio |
-6.97
|
0
|
| Operating Income Ratio |
-6.97
|
0
|
| Total Other Income/Expenses Net |
$6.95 M
|
$118.00 K
|
| Income Before Tax |
-$169.93 M
|
-$226.79 M
|
| Income Before Tax Ratio |
-6.69
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
| Net Income |
-$169.93 M
|
-$226.79 M
|
| Net Income Ratio |
-6.69
|
0
|
| EPS |
-1.43 |
-2.04 |
| EPS Diluted |
-1.43 |
-2.04 |
| Weighted Average Shares Out |
$118.56 M
|
$111.25 M
|
| Weighted Average Shares Out Diluted |
$118.56 M
|
$111.25 M
|
| Link |
|
|
